These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11130253)

  • 1. Coordination of care in disease management: opportunities and financial issues.
    Mosley C
    Semin Dial; 2000; 13(6):346-50. PubMed ID: 11130253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESRD in the geriatric population: the crisis of managed care and the opportunity of disease management.
    Steinman TI
    Semin Dial; 2002; 15(2):84-7. PubMed ID: 11952931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. For-profit versus not-for-profit dialysis care for children with end stage renal disease.
    Furth SL; Hwang W; Neu AM; Fivush BA; Powe NR
    Pediatrics; 1999 Sep; 104(3 Pt 1):519-24. PubMed ID: 10469779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forum of the End-Stage Renal Disease Networks' role in implementing the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines.
    Diamond LH; Daly DC
    Adv Ren Replace Ther; 1999 Jan; 6(1):28-35. PubMed ID: 9925147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a continuous renal replacement program in critically ill patients.
    Gilbert RW; Caruso DM; Foster KN; Canulla MV; Nelson ML; Gilbert EA
    Am J Surg; 2002 Dec; 184(6):526-32; discussion 532-3. PubMed ID: 12488156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving adequacy of hemodialysis in Northern California ESRD patients: a final project report. Provider Participants and Medical Review Board of the TransPacific Renal Network.
    Brown J; Josephson M
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S85-94. PubMed ID: 11053593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical Director Responsibilities to the ESRD Network.
    DeOreo PB; Wish JB
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1852-8. PubMed ID: 25255911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
    Park H; Rascati KL; Keith MS
    J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dilemmas of patient treatment for end-stage renal disease.
    Schmidt RW; Blumenkrantz M; Wiegmann TB
    Am J Kidney Dis; 1983 Jul; 3(1):37-47. PubMed ID: 6346866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs of dialysis in the USA.
    Garella S
    Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost of implementing the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines.
    Wish J; Roberts J; Besarab A; Owen WF
    Adv Ren Replace Ther; 1999 Jan; 6(1):67-74. PubMed ID: 9925152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrologists as primary care providers: a review of the issues.
    Holley JL
    Am J Kidney Dis; 1998 Apr; 31(4):574-83. PubMed ID: 9531172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a patient-centered medical home intervention for patients with end-stage renal disease on hemodialysis.
    Porter AC; Fitzgibbon ML; Fischer MJ; Gallardo R; Berbaum ML; Lash JP; Castillo S; Schiffer L; Sharp LK; Tulley J; Arruda JA; Hynes DM
    Contemp Clin Trials; 2015 May; 42():1-8. PubMed ID: 25735489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the ESRD managed care demonstration operations.
    Oppenheimer CC; Shapiro JR; Beronja N; Dykstra DM; Gaylin DS; Held PJ; Rubin RJ
    Health Care Financ Rev; 2003; 24(4):7-29. PubMed ID: 14628397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESRD managed care demonstration: financial implications.
    Dykstra DM; Beronja N; Menges J; Gaylin DS; Oppenheimer CC; Shapiro JR; Wolfe RA; Rubin RJ; Held PJ
    Health Care Financ Rev; 2003; 24(4):59-75. PubMed ID: 14628400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward population management in an integrated care model.
    Maddux FW; McMurray S; Nissenson AR
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):694-700. PubMed ID: 23539229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of end-stage renal disease care in South Asia.
    Jha V
    Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: access to ESRD treatments.
    Hörl WH; de Alvaro F; Williams PF
    Nephrol Dial Transplant; 1999; 14 Suppl 6():10-5. PubMed ID: 10528707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of external oversight in quality activities: accreditation, credentialing, licensure, and deemed status.
    Wish JB
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S177-81. PubMed ID: 9892388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: process, outcomes, and implications.
    Sugarman JR; Frederick PR; Frankenfield DL; Owen WF; McClellan WM;
    Am J Kidney Dis; 2003 Oct; 42(4):806-12. PubMed ID: 14520632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.